Appendix for Organisational changes and challenges for inflammatory bowel disease services in the United Kingdom during the COVID-19 pandemic

Contributors

Richard Appleby Chelsea and Westminster Hospital NHS Foundation Trust

David Armour NHS Highland

Marcus Auth
Alder Hey Children's NHS Foundation Trust
Bijay Baburajan
Maidstone and Tunbridge Wells NHS Trust
John Beckly
Anirudh Bhandare
Pennine Acute Foundation Trust

Stuart Bloom University College London

Nick Bosanko Plymouth University Hospitals Foundation Trust

Mary Brennan Cambridge University Hospitals

Jeff ButterworthShrewsbury and Telford Hospital NHS TrustVida CairnesRoyal Devon and Exeter NHS Foundation TrustFiona CameronAlder Hey Children's NHS Foundation Trust

Iain Chalmers NHS Grampian

Rakesh Choudhary West Hertfordshire Hospitals NHS Trust
Andrew Cole Derby Hospitals NHS Foundation Trust
Joseph Collum East Lancashire Hospitals NHS Trust

Debbie Corris North Bristol NHS Trust

Patsy Daly Great Western Hospitals NHS Foundation Trust
David Devadason Nottingham University Hospitals NHS Trust

Anjan Dhar County Durham & Darlington NHS Foundation Trust
Andrew Fagbemi Royal Manchester Children's Hospital, Manchester
Miss Nicola Fearnhead Cambridge University Hospitals NHS Foundation Trust

Steven Fong East Sussex Healthcare NHS Trust

Aileen Fraser University Hospital Bristol

Becky George Torbay and South Devon NHS Foundation Trust
Lynn Gray Wirral Teaching Hospitals NHS foundation trust
Kay Greveson Royal Free London NHS Foundation Trust

Veronica Hall Bolton NHS Foundation Trust

Heather Hart

James Hart

Royal Devon and Exeter NHS Foundation Trust

Andrew Barney Hawthorne

Bu'Hussain Hayee

Lucy Howarth

Neil Ikin

Sandwell & West Birmingham Hospitals NHS Trust

Royal Devon and Exeter NHS Foundation Trust

Cardiff and Vale University Health Board

King's College Hospital NHS Foundation Trust

Oxford University Hospitals NHS Foundation Trust

Ashford and St Peters NHS Foundation Trust

Tariq Iqbal Kings Lynn NHS Trust

Lisa James Cwm Taf University Health Board

Gareth-Rhys Jones University of Edinburgh Centre for Inflammation Research

Karen Kemp Manchester Royal Infirmary

Beverley Kirkham Kingston Hospital NHS Foundation Trust

Tina Law Warrington and Halton Teaching Hospitals NHS Trust

Wendy Lewis Medway NHS Foundation Trust

Anna Lewis-Williams Countess of Chester Hospital NHS Foundation Trust

Andi Li Western Sussex Hospitals NHS foundation Trust

Zia Mazhar Basildon and Thurrock University Hospitals NHS Foundation Trust

Lou-Anne Mccabe Winchester and Eastleigh Healthcare Trust

Andrew Milestone Wye Valley NHS Trust

Rajiv Mohan University Hospitals of Leicester NHS Trust
Deborah Morris East and North Hertfordshire NHS Trust
Priya Narula Sheffield Children's NHS Foundation Trust

Joanne Parker Brighton and Sussex University Hospitals NHS Trust.

Anna Pigott University Hospitals of North Midlands NHS Trust

Nick Powel Imperial College Healthcare NHS Trust

Elizabeth Renji Newcastle upon Tyne Hospitals NHS Foundation Trust Nicholas Reps St George's University Hospitals NHS Foundation Trust

Gerry Robins York Teaching Hospitals NHS Foundation Trust Richard Russell Royal Hospital for Sick Children, Edinburgh

Santosh S Salunke Forth Valley Royal Hospital

Sunil Samuel Nottingham University Hospitals NHS Trust
Shahzad Sarwar North Lincolnshire and Goole Foundation Trust

Richard Shenderey Airedale NHS Foundation Trust

Jo Sims Bradford Teaching Hospitals NHS Foundation Trust

Ganesh Sivaji Harrogate & District NHS Foundation Trust

Jayne Slater Dudley Group NHS Foundation Trust

Philip Smith Newcastle upon Tyne Hospitals NHS Foundation Trust,

Emma Smith Women's and Children's NHS Foundation Trust

Richard Speight Newcastle upon Tyne Hospitals NHS Foundation Trust,

Sreedhar Subramanian Royal Liverpool and Broadgreen University Hospitals NHS Trust

Iola Thomas Betsi Cadwaladr University Health Board

Franco Torrente Cambridge University Hospitals

Ajay Verma Kettering General NHS Foundation Trust

Amar Wahid Cardiff and Vale University Health Board

Emma Wesley Taunton and Somerset NHS Foundation Trust

Lisa Whitley University College London

Veena Zamvar Leeds University Teaching Hospitals

Challenges and organisational changes in IBD units during COVID-19 Pandemic

The IBD teams and services they provide are under mounting pressures following the onset of the COVID-19 Pandemic. We wanted to survey IBD teams on the impact of these challenges on their services and identify any learning points for services to adopt. We would appreciate if you could take take 10 mins of your time and fill in the following questionnaire. This is anonymous and no personal identifiable information is collected.

Thank you

From UK IBD Covid-19 Working Group *Required

Ι.	I am
	Mark only one oval.
	IBD nurse
	Gastroenterologist with interest in IBD
	Colorectal surgeon with interest in IBD
	IBD infusion nurse
	IBD pharmacist
	Paediatric Gastroenterologist
	Paediatric IBD nurse

Mark	only one oval.
	London
	South East
	South West
	East Midlands
	West Midlands
	East of England
	Yorkshire and Humber
	North East
	North West
	Wales
	Scotland
	Scotland Northern Ireland
	Northern Ireland hospital is our IBD team based ?
	Northern Ireland
Type o	Northern Ireland hospital is our IBD team based ?
Type o	Northern Ireland hospital is our IBD team based ? f hospital
Type o	hospital is our IBD team based ? f hospital only one oval.

5.	IBD clinic characteristic <i>Mark only one oval.</i>
	General gastroenterology clinic
	Dedicated IBD unit
6.	Approximately how many IBD patients are currently under your care *
	Mark only one oval.
	<500
	501-1000
	1001-2000
	2001-3000
	>3000
7.	Number of consultant gastroenterologists providing regular outpatient care to IBD patients prior to COVID-19 pandemic (eg: establishment on 1st Jan 2020) <i>Mark</i>
	only one oval.
	3-5
	6-9
	>/=10

8.	Number of consultant gastroenterologists providing inpatient care to IBD patients prior
	to COVID-19 pandemic (eg: establishments on 1st Jan 2020) Mark only one oval.
	_ 1
	3
	4
	<u> </u>
	<u> </u>
	7
	8
	9
	10 or more
9.	Number of gastroenterologists currently providing outpatient IBD care now (as of 10th April 2020)
	Mark only one oval.
	o
	_ 1
	3
	4
	<u> </u>
	6
	7
	8
	9
	10 or more

10.	If reduction in gastroenterologists providing IBD care now, what is the reason (Please click all that apply) Tick all that apply.
	Redeployment
	Isolating due to COVID19 symtoms
	Belongs to shielding category
	Sick due to non COVID19 reason
	Not applicable -there is no reduction in our unit
	Other:
11.	What is the minimum number WTE of consultant gastroenterologists required to provide IBD care in your unit? (please write a number)
12.	Figure 1: Likelihood of having less than the minimum required WTE of
	gastroenterologists during COVID-19 Mark only one oval.
	Certainly
	Very likely
	Likely
	Unlikely
13.	Number of IBD Nurses in your unit prior to COVID-19 (eg: establishment on 1st Jan 2020)
	Mark only one oval.
	o
	1
	<u> </u>
	<u> </u>
	>5
	7

14.	Number of IBD nurses available exclusively for IBD care now- as of 10th th April 2020
	Mark only one oval.
	0 1
	\bigcirc 2
	4
	<u> </u>
	>5
	Other:
15.	If reduction in IBD nurse numbers , the reason (Click all that apply) Tick all that apply.
	Redeployment
	☐ Isolating due to COVID19 symptoms ☐ Shielding
	Sick leave due to non COVID reason
	Not applicable as no reduction in numbers
	Other:
16.	What is the minimum number (WTE) of IBD nurses required to provide IBD care in your unit? (please write a number)
17.	Figure 2: Likelihood of having less than the minimum required IBD nurses due to
	redeployment and self isolation during COVID-19 pandemic <i>Mark only one oval.</i>
	Certainly
	Very likely
	Likely
	Unlikely
	C

18.	Provision of IBD clinics (please select all options that apply)
	Tick all that apply.
	Keep running face to face clinics as before
	Running face to face clinics with reduced capacity
	Complete cancellation of routine clinics
	Substitution of face to face clinics by telephone consultation
	Substitution of face to face clinics by video consultation Other:
19.	Approximately what proportion of patients are using telephone consultations
	Mark only one oval.
	<25%
	25-50%
	50-75%
	100%
	No telephone consultations
20.	Approximately what proportion of patients are using video consultations
	Mark only one oval.
	No video consultation facility
	10%
	20%
	30%
	40%
	50%
	>50%

21.	Are you currently using/planning to use any IBD patient apps for out patient IBD care
	Mark only one oval.
	Yes - currently using
	No
	Yes- currently in set up
	Other:
22.	Figure 4: IBD Endoscopy provision during COVID-19 pandemic
	Tick all that apply.
	Surveillance of dysplasia in patients with IBD
	Assessment of disease activity in outpatients
	Outpatient diagnosis in all suspected IBD
	Assessment of admitted patients with acute IBD
	Clinical trial protocol scopes
	All IBD endoscopy provision cancelled
23.	Current provision for IBD surgery (please select all that apply)
	Tick all that apply.
	Keep running elective out patient resections
	Emergency small bowel resections
	Colectomy for acute severe colitis
	Perianal surgery for perianal sepsis
	Colectomy for IBD dysplasia
	No IBD surgery at all

24.	What changes have you made to Infusion unit in light of COVID-19 (Please select all that apply)
	Tick all that apply.
	Cancellation of all treatments
	Moved the infusion facility to a "safe site"
	Maintain treatments with protective measures (Distancing >2m, surgical mask usage etc)
	Change from IV to subcut treatments
	check list of suspicious COVID-19 symptoms prior to the administration of treatments
	Delaying Treatments
	Staff using masks
	Patient using masks
25.	Are patients cancelling their attendance to infusion clinics (Click all that apply) Tick all that apply.
	□ No
	Yes approximately 10%
	Yes approximately 25%
	Yes approximately 50%
	Cancelling >50%
	Other:
26.	Reasons reported for patients cancelling biologic infusion unit attendance
	Tick all that apply.
	Self isolating due to suspected/COVID19 symptoms
	Self isolating due to contact with COVID-19 positive
	Chose not to attend due to worry about the effect of drugs
	Unable to get to the relocated infusion unit
	Other:

27.	Is your IBD service cancelling scheduled biologics infusions
	Mark only one oval.
	No
	Yes approximately 10%
	Yes approximately 25%
	Yes approximately 50%
	Cancelling more than 50%
28.	Reason for service cancelling scheduled biologics infusions
	Tick all that apply.
	Staff shortage
	COVID-19 symptoms
	No adequate facility to deliver infusions
	Abnormal safety bloods
	Not applicable - no service cancellations
29.	Are you currently able to initiate new home care prescriptions of S/C biologics?
	Mark only one oval.
	Yes
	No
30.	Is there any disruption to home care prescriptions and delivery in patients who are already established on S/C biologics?
	Mark only one oval.
	Yes
	○ No

31.	Please give details if there is disruption in initiation of new or continuation of existing home care services for s/c biologics (Click more than one if applicable)
	Tick all that apply.
	Home care services interrupted due to challenges in blood monitoring
	Home care services interrupted due to provider (healthcare at home) issues
	Home care services interrupted due to pharmacy issues
	Disruption due to lack of provision to do safety bloods
	Disruption due to reduced number of IBD nurses
	Not applicable as currently no disruption in home care services
32.	What have you done about provision of iron infusions since COVID-19 pandemic
	Mark only one oval.
	Iron infusions stopped
	Iron infusions curtailed
	Normal service for iron infusions
	Other:
33.	Provision of IBD MDTS since COVID-19 pandemic (Select more than one if applicable) <i>Tick all that apply.</i>
	F2F MDTS as normal/reduced numbers but with social distancing
	Virtual MDTs
	MDTs reduced in frequency
	MDTs cancelled
	We never had separate IBD MDTs
	Other:

34.	Figure 5: Current provision of laboratory faecal calprotectin tests during COVID- 19 pandemic
	Mark only one oval.
	Normal service as before
	Reduced access to lab calprotectin
	Increased access to lab calprotectin
	No access to lab calprotectin
35.	What is the current provision of point of care (POC) calprotectin tests in your service since COVID-19 pandemic
	Tick all that apply.
	☐ Introduced
	Scaled up Never had one
	Wish to do but have local barriers
36.	Blood Monitoring of Immunomodulators since COVID-19
	pandemic(AZA,MP,Methotrexate) Mark only one oval.
	The same intervals of monitoring
	Less frequent monitoring All
	routine monitoring suspended
	Other:

37.	Provisions to assess patients with established IBD having a flare in your service since COVID-19 pandemic
	Tick all that apply.
	Face to Face review in flare clinics/Hot clinics
	Access to Calrotectin
	Access to bloods (eg: CRP) in primary care
	Access to bloods (eg:CRP) in secondary care
38.	Figure 3: Impact on IBD helpline since COVID-19 pandemic
	Mark only one oval.
	No change in activity
	>10% increase in IBD telephone helpline/email activity
	>25% increase in IBD telephone helpline/email activity
	>50% increase in IBD telephone helpline/email activity
	100% increase in telephone helpline/e-mail activity
	150% increase in telephone/e-mail activity
	200% increase in telephone/e-mail activity
39.	Changes made to IBD helpline since COVID-19 pandemic(Please select all that apply)
	Tick all that apply.
	Automated email response with frequently asked questions
	Automated voice message with frequently asked questions
	Increased number of staff manning helpline
	More contact options provided
	No change from before
	Reduced number of staff manning helplines
	IBD helplines shut down
	We did not have IBD helpline before

40.	Impact of COVID-19 on provision of other services by the IBD nurses (Please select all that apply)
	Tick all that apply.
	Normal service as before
	Inpatient IBD nurse services curtailed
	In patient IBD nurse services stopped
	Out patient IBD nurse clinics curtailed
	Outpatient IBD nurse clinics stopped
	Outpatient IBD nurse clinics continuing as normal F2F
	Outpatient IBD nurse clinics continuing as telephone or video consultation Restricted
	to working from Home
41.	Dissemination of the BSG IBD risk grid from your service (Please select all that apply)
	Tick all that apply.
	Have completed indentification of the BSG IBD CCUK risk grid
	Have sent letters to high risk patients based on risk
	Have sent letters to moderate risk patients as per grid
	Have sent letters to all IBD patients
	Have mentioned registry tool (https://www.ibdgregistry.org.uk/covid-19) in letters
	sent out to patients
42.	Are you entering IBD patients with COVID-19 into the SECURE IBD registry https://covidibd.org ?
	Mark only one oval.
	Yes - have entered already
	Yes- not entered yet but will enter
	○ No